
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology
IMNN-101 induced 2- to 4-fold increase in neutralizing antibody (NAb) titers from baseline through Week 4
IMNN-101 continues to show an acceptable safety profile
LAWRENCEVILLE, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced new safety and immunogenicity data from ongoing analyses of results from the Company's first Phase 1 proof-of-concept clinical trial of IMNN-101, its investigational DNA plasmid vaccine based on the Company's proprietary PlaCCine® technology platform. The Phase 1 study was conducted in 24 healthy volunteers as a seasonal COVID-19 vaccine, targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen. IMNN-101 was administered as a single dose vaccine without a booster dose in study participants who were previously vaccinated against the Omicron XBB1.5 variant. Results demonstrated that IMNN-101 is safe and well-tolerated with no serious adverse effects. IMNN-101 induced a persistent 2- to 4-fold increase in serum neutralizing antibody (NAb) titers from baseline through Week 4, further increasing NAb titers between Week 2 and Week 4. The immune response was observed against the XBB1.5 variant and many newer variants following treatment, demonstrating the IMNN-101 vaccine's cross-reactivity.
'We have strong evidence of vaccine immunogenicity based on the neutralizing antibody response against the Omicron XBB.1.5 strain in this trial, and expect partnering interest in our proof-of-concept data from the PlaCCine platform,' said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. 'These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing vaccine candidates for protecting the population against a potential future exposure to a pathogen or controlling a rising pathogen. Given proof of immunogenicity, early indications of durability of protection, and competitive advantages in the stability of our vaccine at workable temperatures compared with available mRNA vaccines, we believe that IMNN-101 has significant potential as a superior next-generation vaccine and will seek potential partners for further development.'
The participants in the Phase 1 trial had high baseline immune characteristics presumably from prior infection and multiple previous vaccinations against COVID-19 and ongoing infection as evidenced by the rise in viral nucleocapsid antigen during the study period. Modest increases in T cell responses were observed in this setting of trial participants having received multiple immunizations prior to the study.
'Data from this trial is of high quality and show that IMUNON's DNA vaccine is immunogenic in humans. Following immunization, participants' NAb titers increased through Week 4 with a 2- to 4-fold increase from baseline, a clear and convincing response to the vaccination,' said Ai-ris Collier, M.D., Co-Director of the Clinical Trials Unit, Center for Virology and Vaccine Research Center, Beth Israel Deaconess Medical Center.
The Phase 1 clinical data of IMNN-101 is consistent with strong evidence of immunogenicity and protection for the PlaCCine platform in rodents and non-human primates, with prior preclinical results showing that protection exceeded 95% in non-human primates, which is comparable to mRNA vaccines. The robust immunogenicity profile, expected durability of protection, comparative ease of manufacturing, and stability at workable temperatures (up to one year at 4°C and one month at 37°C) suggest that our vaccine based on the PlaCCine technology platform may be a potential viable alternative to available messenger RNA (mRNA) vaccines.
About PlaCCine® and IMNN-101
IMNN-101 utilizes the company's PlaCCine® technology platform, a proprietary composition of a DNA plasmid that regulates the expression of key pathogen antigens and a novel synthetic DNA delivery system. The plasmid-based expression vector accommodates single or multiple antigens through its flexible vector design, offers manufacturing flexibility compared to with viral or other DNA or protein vaccines, and the synthetic delivery system protects DNA from degradation and facilitates DNA uptake after injection with acceptable safety.
About the Phase 1 PoC Clinical Trial
This U.S. Phase 1 proof-of-concept (PoC) study inoculated 24 participants to evaluate three escalating doses of IMNN-101 with eight participants at each dose. All participants were treated at DM Clinical Research in Philadelphia. For this study, IMNN-101 has been designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, in accordance with the FDA's Vaccines and Related Biological Products Advisory Committee's June 2023 announcement of the framework for updated COVID-19 doses. The primary objectives of the study are to evaluate safety and tolerability in healthy adults. Secondary objectives include evaluating IMNN-101's ability to elicit neutralizing antibody responses, cellular responses and their associated durability.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing for commencement and potential outcome of a Phase 3 trial of IMNN-001, the timing and enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, the potential partnering opportunities, and the Company's plans and expectatio
ns with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Roll-to-Roll Technologies for Flexible Devices Set to Grow at 11.5% CAGR
"Comprehensive Market Analysis Highlights Key Drivers, Emerging Technologies, and Competitive Landscape for Roll-to-Roll Technologies in Flexible Devices" Boston, June 10, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Markets for Roll-to-Roll Technologies for Flexible Devices' is expected to reach $69.8 billion by the end of 2029 at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2029. The report offers an in-depth analysis of roll-to-roll (R2R) technologies for flexible devices, covering various device types and fabrication processes. It identifies current and emerging devices and provides detailed market segmentation by process category, substrate material, deposition method, end-use industry and region. The report includes a technological review of the fabrication steps and highlights the most active research organizations in this field and their activities. The rapid advancements in flexible electronics provide valuable insights into the market size, growth trends, players and emerging applications of R2R technologies. The report highlights the increasing demand for flexible and wearable devices, driving the adoption of R2R technologies for cost-effective, high-volume production. Additionally, the rising demand for R2R-produced solar cells and flexible devices in consumer electronics, optoelectronics and the automotive industry makes this report particularly timely and vital. The factors driving the market include: Demand for Flexible Devices: Flexible devices are increasingly popular in consumer electronics (like foldable phones), optoelectronics (such as OLED displays), and the automotive industry (for smart sensors and displays). They offer portability, durability, and innovative designs. Rising Demand for R2R-Produced Solar Cells: Roll-to-Roll technology enables cost-effective, flexible solar panels. These are crucial for renewable energy solutions, making solar power more accessible and versatile. Request a sample copy of the global market for R2R technologies for flexible devices report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $37.0 billion Market size forecast $69.8 billion Growth rate CAGR of 11.5% for the forecast period of 2024-2029 Segments covered Process category, substrate material, deposition method, end-use industry, and region Regions covered North America, Europe, Asia-Pacific, and the Rest of the world Countries covered The U.S., Canada, the U.K., Germany, France, Italy, China, India, Japan, Taiwan, and the Middle East and Africa Market drivers Growing demand for flexible devices across consumer electronics, optoelectronics and the automotive industry. Rising demand for R2R-produced solar energy and solar cells globally. Interesting facts: According to the Taiwan Printed Circuit Association (TPCA) and the Industrial Technology Research Institute (ITRI), in 2023, Taiwanese companies are the leading suppliers of flexible Printed Circuit Boards (PCBs), accounting for approximately 34.5% of the total market value. The U.S. accounted for more than 71% of the North American R2R technologies for flexible devices market. Asia-Pacific is expected to grow at the fastest CAGR of 12.8% from 2024 to 2029. In 2024, Several Indian companies, including Dixon Technologies, expanded their production capacities to cater to the growing demand for flexible devices. Dixon is expected to invest $176.7 million to $ 212.1 million in the next three years to expand its production capacity and component manufacturing. Emerging startups: GraphenicaLab: Founded in 2016, GraphenicaLab, a spin-off of Barcelona's Catalan Institute of Nanoscience and Nanotechnology (ICN2), leverages a patented state-of-the-art technology to print flexible graphene sensors and electronic devices directly onto various surfaces. GraphenicaLab has leveraged the extraordinary properties of graphene- the world's thinnest, lightest and strongest material. Delft Circuits BV: Founded in 2016, Delft Circuits provides hardware solutions for quantum engineers and industries. Delft has established itself as a trusted provider of cutting-edge quantum technology with hundreds of I/O modules delivered to nearly a hundred clients, including leading national laboratories, blue-chip corporations, and ambitious academic researchers. The report addresses the following questions: What is the projected market size and growth rate of the global market R2R technologies for flexible devices? The market was valued at $37.0 billion in 2023 and will reach $69.8 billion by the end of 2029, growing at a CAGR of 11.5% from 2024 to 2029. What factors are driving the growth of the R2R technologies for flexible devices market? The growing demand for flexible devices across consumer electronics, optoelectronics, and the automotive industry. Rising demand for R2R-produced solar energy and solar cells. Which end-use industry segment will dominate the market by the end of 2029? The consumer electronics segment will continue to dominate the market. Which region has the largest market share in the global R2R technologies for flexible devices market? The Asia-Pacific region has the largest share in the global market. Leading companies in the market include: 3M ALL FLEX SOLUTIONS APPLIED MATERIALS INC. ASCENT SOLAR TECHNOLOGIES INC. AUO CORP. CAREER TECHNOLOGY (MFG.) CO. LTD. E INK HOLDINGS INC. FLEXIUM INTERCONNECT INC. FUJIKURA LTD. HELIATEK INTERFLEX CO. LTD. JOHNSON ELECTRIC HOLDINGS LTD. MOLEX PANASONIC HOLDINGS CORP. SAMSUNG SUMITOMO ELECTRIC INDUSTRIES LTD. Related reports include: Advanced Materials for 3D Printing: Technologies and Global Markets: The report comprehensively analyzes the global market for advanced materials used in 3D printing. It examines the market by material (plastics and polymers, metals), technology (vat polymerization, powder bed fusion, material extrusion), end-user industries (transportation, medical and dental, consumer products and electronics, industrial machinery), and region (Asia-Pacific, Europe, North America, the Rest of the World). Printed Circuit Boards: Technologies and Global Markets: The report analyzes current trends in the global market for printed circuit boards (PCBs). It covers global revenue for five market segments (assembly technology, PCB type, PCB structure, PCB thickness and end-user industry) across four regions (North America, Europe, Asia-Pacific, and the Rest of the World). The report explores growth drivers and challenges of the market, leading PCB manufacturers, emerging technologies, competitive and technological differentiators, and environmental, social, and governance (ESG) developments in the industry. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
JumpCloud & Deel IT Unite for Seamless Provisioning
LOUISVILLE, Colo., June 10, 2025 /PRNewswire/ -- JumpCloud Inc. has partnered with Deel IT to simplify global device management. This collaboration helps businesses manage devices and security for employees worldwide. Managing IT for global teams brings unique challenges. Traditional methods struggle with outdated, centralized systems that can't adapt to diverse international operations and local regulations. Companies deal with problems such as: Time-consuming manual tasks Complex compliance rules Inventory issues Slow onboarding for new international hires IT teams can now conquer operational hurdles and security concerns with a powerful combined solution from JumpCloud and Deel IT, designed to streamline their workflows. Through this partnership, customers will gain key advantages, including: Receive ready-to-use devices: Your new devices arrive pre-configured with all necessary security settings and automated updates, enabling immediate and secure use. Benefit from day-one security compliance: You can be confident that all your devices automatically meet your security standards from the moment they're deployed, significantly reducing your risk exposure. Simplify your global device management: You can offload the complexities of managing devices worldwide—from initial procurement all the way through to repurposing and secure disposal—freeing up your IT team for other priorities. Application management: JumpCloud ensures secure software access, saving IT teams time. "This partnership with JumpCloud unlocks a new level of simplicity for global teams, no matter where they work," said Sami Bouremoum, general manager, Deel IT. "By streamlining device provisioning and security across borders, we're helping IT teams move faster and deliver a seamless, secure experience to distributed team members, wherever they are in the world." This integrated approach helps businesses expand into new talent regions with confidence. IT teams can onboard employees and manage equipment consistently, regardless of location. This reduces operational costs and enhances security. "Running a global business requires intelligent IT solutions," said Joel Rennich, senior vice president, product management, JumpCloud. "Our partnership with Deel IT provides a powerful way to manage devices and keep teams secure, no matter where they are." To learn more about combining JumpCloud and Deel IT to support your workforce, visit the blog post here. About Deel Deel is the all-in-one payroll and HR platform for global teams. Built for the way the world works today, Deel combines payroll, HRIS, compliance, benefits, performance, and equipment management into one seamless platform. With AI-powered tools and a fully owned payroll infrastructure, Deel supports every worker type in 150+ countries—helping businesses scale smarter, faster, and more compliantly. Discover how Deel makes global work simple at About JumpCloud JumpCloud® delivers a unified identity, device, and access management platform that makes it easy to securely manage identities, devices, and access across your organization. With JumpCloud, IT teams and MSPs enable users to work securely from anywhere and manage their Windows, Apple, Linux, and Android devices from a single platform. Learn more: Follow us: Blog | Community | Podcast | X | LinkedIn | YouTube | Resources Click here to get started with JumpCloud Contact For JumpCloud Josie Judy press@ View original content: SOURCE JumpCloud, Inc.
Yahoo
32 minutes ago
- Yahoo
Success Story Podcast Announces New Episode Featuring Billionaire Grant Cardone on Wealth and Leadership
Billionaire Real Estate Mogul Grant Cardone Reveals Why He "Should Be Worth $20 Billion Today" and Shares Unconventional Success Blueprint $4 Billion Empire Builder Discusses Breaking Comfort Zone Addiction, Choosing the Right "Vehicle" for Wealth, and Why Most People Have "Quit on Money" Cardone also hints at major announcement coming "within the week" and reconsiders California political ambitions Miami, Florida , June 10, 2025 (GLOBE NEWSWIRE) -- Success Story Podcast, hosted by Scott Clary, has announced a new episode featuring billionaire entrepreneur and Cardone Ventures CEO Grant Cardone. In this exclusive conversation, Cardone shares unfiltered insights on building generational wealth, the hidden challenges of leadership, and the mindset shifts that separate top performers from the rest. The episode offers listeners a candid look at Cardone's personal journey and practical strategies for achieving extraordinary success. Grant Cardone, the outspoken billionaire behind a $4 billion real estate empire and bestselling author of "The 10X Rule," delivered hard-hitting insights about wealth creation, leadership isolation, and the critical decisions that separate the ultra-successful from everyone else in a revealing interview on Scott Clary's Success Story podcast. The $20 Billion Revelation In a candid moment, Cardone stated he "should be worth $20 billion today," attributing the gap to strategic vehicle choices rather than effort or mindset. "The difference between me and my friend who gained $9 billion in two weeks isn't the mindset – we both want abundance and to help millions of people. The difference is the vehicle," Cardone explained, referencing a friend who recently experienced massive volatility, gaining $5 billion in one day before losing $6 billion the following Friday. The Comfort Zone Trap Cardone identified "comfort" as a dangerous addiction that prevents breakthrough success. "Comfortable is a serious addiction that allows you to socially drift through life. You're on a drug of 'I don't want to take risk, I don't want to feel stressed, I just want enough,'" he warned. He revealed that even after making his first million dollars, he fell into this trap: "I went into conservation mode, not hunger mode. What I should have done is 10X that million." Why Most People Have "Quit on Money" Addressing widespread financial struggles, particularly citing Toronto's housing crisis where million-dollar condos are unattainable for $70K earners, Cardone argued that most people have psychologically given up on wealth creation. "I think most people have quit on the money game. They're like, 'I'm not going to have it. The game's rigged. I just need to be happy,'" he observed. His solution is radical target-setting: "Your target should be monster. Make a 100X exit. Then find out whether the business you're in right now can actually get you to that target." The Leadership Loneliness Factor Cardone opened up about the isolation that comes with high-level decision-making, comparing his experience to Donald Trump's situation. "Do you know how lonely Donald Trump must be? There is no way that guy's doing what he's doing on a daily basis that he gets support from everybody around him," he reflected. "If you're in a leadership position, you're going to be in a situation one day where you got to go take a hill and you're going to look up – you're by yourself." Controversial Education and Parenting Philosophy The billionaire continued his criticism of traditional education paths, stating most people "should not go to college" and calling the current system "insanity." For parenting, he advocates extreme engagement: "You cannot turn them over to YouTube and Facebook. Those are not nannies. Get your kids off TV, get your kids off YouTube, get your kids active." Cardone homeschools his children year-round and requires them to work under contract since age six, resulting in his 15-year-old daughter graduating high school at 15. Political Ambitions in Question In a rare moment of uncertainty, Cardone revealed he's "second-guessing the whole California thing," referring to his consideration of entering California politics to "flip it red." Despite believing he "could win it," he's questioning whether to pursue the opportunity given other priorities. The Ultimate Success Formula When asked for the single most important lesson he'd pass to his children, Cardone delivered his core philosophy: "You will never get anything great without leaving something good." About Success Story Podcast The Success Story podcast, hosted by Scott Clary, features in-depth conversations with the world's most successful entrepreneurs, investors, and business leaders. Known for extracting actionable insights and candid revelations, the show has become a premier destination for ambitious professionals seeking real-world business wisdom. Watch the full interview: About Grant Cardone Grant Cardone is a New York Times bestselling author, sales expert, real estate investor, and entrepreneur who has built a $4 billion real estate portfolio. He is the founder and CEO of Cardone Capital and Cardone Ventures, and the author of several business books including "The 10X Rule." Known for his no-nonsense approach to business and wealth building, Cardone has trained Fortune 500 companies and speaks to hundreds of thousands annually about sales, business, and success strategies. About Success Story Podcast The Success Story Podcast is hosted by entrepreneur, business executive, author, educator and speaker Scott D. Clary. On Success Story, he conducts candid conversations with some of the most prolific business and thought leaders in the world. The podcast ranks as a Top 10 business podcast and Top 3 Education/Self Development podcast, with over 50 million downloads. It is part of the HubSpot Podcast Network and Cheddar. Clary's weekly business newsletter reaches over 321,000 subscribers, sharing valuable insights from his experiences throughout his career. Press inquiries Success Story Podcast Scott D. Clary scott@ A video accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data